Adjuvant therapy for resected high-risk colon cancer: Current standards and controversies

Por Gill, Sharlene
Publicado em 2014

Racial differences in the incidence of colorectal cancer

Por Virk, Rukinder, Gill, Sharlene, Yoshida, Eric, Radley, Simon, Salh, Baljinder
Publicado em 2010

The identification of Lynch syndrome in British Columbia

Por Cremin, Carol M, Armstrong, Linlea, Gill, Sharlene, Huntsman, David, Bajdik, Chris
Publicado em 2009

Lynch syndrome-chasing a better ascertainment rate in British Columbia

Por Cremin, Carol, Bashash, Morteza, Armstrong, Linlea, Gill, Sharlene, Huntsman, David, Bajdik, Chris
Publicado em 2010

Chemotherapy regimens for advanced pancreatic cancer: a systematic review and network meta-analysis

Por Gresham, Gillian K, Wells, George A, Gill, Sharlene, Cameron, Christopher, Jonker, Derek J
Publicado em 2014

Relationship of ethnicity and overall survival in patients treated with sorafenib for advanced hepatocellular carcinoma

Por Peixoto, Renata D’Alpino, Renouf, Daniel J., Gill, Sharlene, Cheung, Winson Y., Lim, Howard J.
Publicado em 2014

Effect of M1a and M1b Category in Metastatic Colorectal Cancer

Por Kennecke, Hagen, Yu, Jason, Gill, Sharlene, Cheung, Winson Y., Blanke, Charles D., Speers, Caroline, Woods, Ryan
Publicado em 2014

Impact of Irinotecan and Oxaliplatin on Overall Survival in Patients With Metastatic Colorectal Cancer: A Population-Based Study

Por Lim, Howard J., Gill, Sharlene, Speers, Caroline, Melosky, Barbara, Barnett, Jeff, Fitzgerald, Catherine, O'Reilly, Susan, Kennecke, Hagen
Publicado em 2009

Adjuvant Chemotherapy for Resected Stage II and III Colon Cancer: Comparison of Two Widely Used Prognostic Calculators

Por Bardia, Aditya, Loprinzi, Charles, Grothey, Axel, Nelson, Garth, Alberts, Steven, Menon, Smitha, Thome, Stephan, Gill, Sharlene, Sargent, Dan
Publicado em 2010

In a ‘real-world’, clinic-based community setting, sorafenib dose of 400 mg/day is as effective as standard dose of 800 mg/day in patients with advanced hepatocellular carcimona, w...

Por Shingina, Alexandra, Hashim, Al Moutaz, Haque, Mazhar, Suen, Michael, Yoshida, Eric M, Gill, Sharlene, Donnellan, Fergal, Weiss, Alan A
Publicado em 2013

Prognostic Web-based Models for Stage II and III Colon Cancer: a Population and Clinical Trials-based Validation of Numeracy and Adjuvant! Online

Por Gill, Sharlene, Loprinzi, Charles, Kennecke, Hagen, Grothey, Axel, Nelson, Garth, Woods, Ryan, Speers, Caroline, Alberts, Steven R., Bardia, Aditya, O’Connell, Michael J., Sargent, Daniel J.
Publicado em 2011

Relationship Between Metformin Use and Recurrence and Survival in Patients With Resected Stage III Colon Cancer Receiving Adjuvant Chemotherapy: Results From North Central Cancer T...

Por Singh, Preet Paul, Shi, Qian, Foster, Nathan R., Grothey, Axel, Nair, Suresh G., Chan, Emily, Shields, Anthony F., Goldberg, Richard M., Gill, Sharlene, Kahlenberg, Morton S., Sinicrope, Frank A., Sargent, Daniel J., Alberts, Steven R.
Publicado no Oncologist (2016)

Alcohol consumption and colon cancer prognosis among participants in North Central Cancer Treatment Group phase III trial N0147

Por Phipps, Amanda I., Shi, Qian, Limburg, Paul J., Nelson, Garth D., Sargent, Daniel J., Sinicrope, Frank A., Chan, Emily, Gill, Sharlene, Goldberg, Richard M., Kahlenberg, Morton, Nair, Suresh, Shields, Anthony F., Newcomb, Polly A., Alberts, Steven R.
Publicado no Int J Cancer (2016)

Association between DPYD c.1129-5923 C>G/hapB3 and severe toxicity to 5-fluorouracil-based chemotherapy in stage III colon cancer patients: NCCTG N0147 (Alliance)

Por Lee, Adam M., Shi, Qian, Alberts, Steven R., Sargent, Daniel J., Sinicrope, Frank A., Berenberg, Jeffrey L., Grothey, Axel, Polite, Blase, Chan, Emily, Gill, Sharlene, Kahlenberg, Morton S., Nair, Suresh G., Shields, Anthony F., Goldberg, Richard M., Diasio, Robert B.
Publicado no Pharmacogenet Genomics (2016)

Effect of Oxaliplatin, Fluorouracil, and Leucovorin With or Without Cetuximab on Survival Among Patients With Resected Stage III Colon Cancer: A Randomized Trial

Por Alberts, Steven R., Sargent, Daniel J., Nair, Suresh, Mahoney, Michelle R., Mooney, Margaret, Thibodeau, Stephen N., Smyrk, Thomas C., Sinicrope, Frank A., Chan, Emily, Gill, Sharlene, Kahlenberg, Morton S., Shields, Anthony F., Quesenberry, James T., Webb, Thomas A., Farr, Gist H., Pockaj, Barbara A., Grothey, Axel, Goldberg, Richard M.
Publicado em 2012

Comparison of FOLFIRI With or Without Cetuximab in Patients With Resected Stage III Colon Cancer; NCCTG (Alliance) Intergroup Trial N0147

Por Huang, Jocelin, Nair, Suresh G., Mahoney, Michelle R., Nelson, Garth D., Shields, Anthony F., Chan, Emily, Goldberg, Richard M., Gill, Sharlene, Kahlenberg, Morton S., Quesenberry, James T., Thibodeau, Stephen N., Smyrk, Thomas C., Grothey, Axel, Sinicrope, Frank A., Webb, Thomas A., Farr, Gist H., Pockaj, Barbara A., Berenberg, Jeffrey L., Mooney, Margaret, Sargent, Daniel J., Alberts, Steven R.
Publicado em 2013